BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15753649)

  • 1. BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer.
    Ciampi R; Knauf JA; Rabes HM; Fagin JA; Nikiforov YE
    Cell Cycle; 2005 Apr; 4(4):547-8. PubMed ID: 15753649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
    Ciampi R; Knauf JA; Kerler R; Gandhi M; Zhu Z; Nikiforova MN; Rabes HM; Fagin JA; Nikiforov YE
    J Clin Invest; 2005 Jan; 115(1):94-101. PubMed ID: 15630448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new mechanism of BRAF activation in human thyroid papillary carcinomas.
    Fusco A; Viglietto G; Santoro M
    J Clin Invest; 2005 Jan; 115(1):20-3. PubMed ID: 15630436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors.
    Zou M; Baitei EY; Alzahrani AS; Al-Mohanna F; Farid NR; Meyer B; Shi Y
    Neoplasia; 2009 Jan; 11(1):57-65. PubMed ID: 19107232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the BRAF gene in thyroid tumors.
    Ciampi R; Nikiforov YE
    Endocr Pathol; 2005; 16(3):163-72. PubMed ID: 16299399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
    Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE
    Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
    Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
    Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
    Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
    Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p27 expression through RAS-->BRAF-->MAP kinase-dependent pathway in human thyroid carcinomas.
    Motti ML; De Marco C; Califano D; De Gisi S; Malanga D; Troncone G; Persico A; Losito S; Fabiani F; Santoro M; Chiappetta G; Fusco A; Viglietto G
    Cell Cycle; 2007 Nov; 6(22):2817-25. PubMed ID: 18032931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.
    Lee JH; Lee ES; Kim YS; Won NH; Chae YS
    Pathology; 2006 Jun; 38(3):201-4. PubMed ID: 16753739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
    Ciampi R; Nikiforov YE
    Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation.
    Hamatani K; Eguchi H; Koyama K; Mukai M; Nakachi K; Kusunoki Y
    Oncol Rep; 2014 Nov; 32(5):1809-14. PubMed ID: 25175022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF T1796A transversion mutation in various thyroid neoplasms.
    Xing M; Vasko V; Tallini G; Larin A; Wu G; Udelsman R; Ringel MD; Ladenson PW; Sidransky D
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1365-8. PubMed ID: 15001635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.